Inbal Samuk1,2, Akin Tekin3, Panagiotis Tryphonopoulos3, Ignacio G Pinto3,4, Jennifer Garcia5, Debbie Weppler3, David M Levi3, Seigo Nishida3, Gennaro Selvaggi3, Phillip Ruiz3,6, Andreas G Tzakis3, Rodrigo Vianna3. 1. Pediatric and Adolescent Surgery, Schneider Children's Medical Center, Sackler School of Medicine, Tel Aviv University, 14 kaplan Street, Petach-Tikvha, 49202, Israel. inbalsabl@clalit.org.il. 2. Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. inbalsabl@clalit.org.il. 3. Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. 4. Universidad de Oviedo, Beca, Spain. 5. Pediatrics, University of Miami, Miami, USA. 6. Pathology, University of Miami, Miami, USA.
Abstract
PURPOSE: To present our experience in abdominal transplantations to manage unresectable abdominal neoplasms in children and to describe the role of extensive surgeries in such cases. METHODS: This is a retrospective study of 22 abdominal transplantations in 21 patients for abdominal tumors over 16 years. Transplantation techniques included liver transplant (LT), multivisceral transplant (MVTx), and intestinal autotransplant (IA). Follow-up intervals ranged from 0.3 to 168 months (median 20 months). RESULTS: LT alone was performed in 15 patients for primary malignant (11) and benign (4) liver tumors. Pathological classification included HB hepatoblastoma (6), HCC hepatocellular cancer (3), hepatic epithelioid hemangioendothelioma HEH (1), angiosarcoma (1), benign vascular tumors (3), and adenoma (1). IA was performed in four patients for lesions involving the root of the mesentery; tumors of the head of pancreas (3) and mesenteric hemangioma (1). MVTx was performed in 2 patients for malignancies; pancreaticoblastoma (1), recurrent hepatoblastoma (1), and in one patient as a rescue procedure after IA failure. Four of the eleven patients who underwent LT for malignant liver tumor had metastatic disease at presentation. Six of them died of recurrent neoplasm (3), transplant-related complications (2), and underlying disease (1). All LT patients who had benign tumors are alive with functioning grafts. All IA patients survived and are on an oral diet, with one patient requiring TPN supplementation. One of the three patients who underwent MVTx died of metastatic disease. CONCLUSIONS: Allo/auto transplantation for abdominal tumors is a valuable modality when conventional treatments fail or are not feasible.
PURPOSE: To present our experience in abdominal transplantations to manage unresectable abdominal neoplasms in children and to describe the role of extensive surgeries in such cases. METHODS: This is a retrospective study of 22 abdominal transplantations in 21 patients for abdominal tumors over 16 years. Transplantation techniques included liver transplant (LT), multivisceral transplant (MVTx), and intestinal autotransplant (IA). Follow-up intervals ranged from 0.3 to 168 months (median 20 months). RESULTS: LT alone was performed in 15 patients for primary malignant (11) and benign (4) liver tumors. Pathological classification included HB hepatoblastoma (6), HCC hepatocellular cancer (3), hepatic epithelioid hemangioendothelioma HEH (1), angiosarcoma (1), benign vascular tumors (3), and adenoma (1). IA was performed in four patients for lesions involving the root of the mesentery; tumors of the head of pancreas (3) and mesenteric hemangioma (1). MVTx was performed in 2 patients for malignancies; pancreaticoblastoma (1), recurrent hepatoblastoma (1), and in one patient as a rescue procedure after IA failure. Four of the eleven patients who underwent LT for malignant liver tumor had metastatic disease at presentation. Six of them died of recurrent neoplasm (3), transplant-related complications (2), and underlying disease (1). All LT patients who had benign tumors are alive with functioning grafts. All IA patients survived and are on an oral diet, with one patient requiring TPN supplementation. One of the three patients who underwent MVTx died of metastatic disease. CONCLUSIONS: Allo/auto transplantation for abdominal tumors is a valuable modality when conventional treatments fail or are not feasible.
Authors: Arianeb Mehrabi; Arash Kashfi; Hamidreza Fonouni; Peter Schemmer; Bruno M Schmied; Peter Hallscheidt; Peter Schirmacher; Jurgen Weitz; Helmut Friess; Markus W Buchler; Jan Schmidt Journal: Cancer Date: 2006-11-01 Impact factor: 6.860
Authors: M Ben-Haim; S Roayaie; M Q Ye; S N Thung; S Emre; T A Fishbein; P M Sheiner; C M Miller; M E Schwartz Journal: Liver Transpl Surg Date: 1999-11
Authors: Tomoaki Kato; Andreas G Tzakis; Gennaro Selvaggi; Jeffrey J Gaynor; Andre I David; Alessandro Bussotti; Jang I Moon; Takehisa Ueno; Werviston DeFaria; Sergio Santiago; David M Levi; Seigo Nishida; Monica L Velasco; Gwen McLaughlin; Erick Hernandez; John F Thompson; Patricia Cantwell; Norman Holliday; Alan S Livingstone; Phillip Ruiz Journal: Ann Surg Date: 2006-06 Impact factor: 12.969
Authors: Andreas G Tzakis; Tomoaki Kato; David M Levi; Werviston Defaria; Gennaro Selvaggi; Debbie Weppler; Seigo Nishida; Jang Moon; Juan R Madariaga; Andre I David; Jeffrey J Gaynor; John Thompson; Erick Hernandez; Enrique Martinez; G Patricia Cantwell; Jeffrey S Augenstein; Anthony Gyamfi; Ernesto A Pretto; Lorraine Dowdy; Panagiotis Tryphonopoulos; Phillip Ruiz Journal: Ann Surg Date: 2005-10 Impact factor: 12.969
Authors: U Cillo; F A Ciarleglio; M Bassanello; A Brolese; A Vitale; P Boccagni; G Zanus; L Zancan; L D'Antiga; P Dall'igna; U Montin; E Gringeri; A Carraro; G Cappuzzo; P Violi; M Baldessin; A Bridda; D F D'Amico; G Perilongo Journal: Transplant Proc Date: 2003-12 Impact factor: 1.066
Authors: Roberta Angelico; Chiara Grimaldi; Carlo Gazia; Maria Cristina Saffioti; Tommaso Maria Manzia; Aurora Castellano; Marco Spada Journal: Cancers (Basel) Date: 2019-10-31 Impact factor: 6.639
Authors: Ioannis A Ziogas; Panagiotis T Tasoudis; Nikolaos Serifis; Sophoclis P Alexopoulos; Martin I Montenovo; Alexandra Shingina Journal: Transplant Direct Date: 2022-01-05
Authors: Christos D Kakos; Ioannis A Ziogas; Charikleia D Demiri; Stepan M Esagian; Konstantinos P Economopoulos; Dimitrios Moris; Georgios Tsoulfas; Sophoclis P Alexopoulos Journal: Cancers (Basel) Date: 2022-03-02 Impact factor: 6.575